Bora Pharmaceuticals looks to enter the cell and gene therapy CDMO space

By Jane Byrne contact

- Last updated on GMT

© GettyImages/Andrew Brookes
© GettyImages/Andrew Brookes

Related tags: CDMO, Bora Pharmaceuticals, cell and gene therapy, macromolecular, Taiwan

Taiwan based contract manufacturer, Bora Pharmaceuticals, in partnership with Taishin Healthcare Limited, is ready to spend millions to expand its footprint in the CDMO sector.

The two parties will jointly invest up to US$108m, targeting “forward-looking”​ contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs).

Bora intends to do so through the deployment of private equity funds and its existing resources.

The company said it intends to leverage this alliance to enter the macromolecular and cell and gene therapy manufacturing space, and by doing so, significantly strengthen its international competitiveness, while driving the growth of Taiwan's CDMO sector.

The CDMO market has huge growth potential, said the organization. 

"In order to effectively allocate resources, international pharmaceutical makers have moved towards specialization over the past few years, resulting in CDMO services becoming a trend sweeping the global biotech pharmaceutical sector,"​ said Bobby Sheng, chairman, Bora Pharmaceuticals.

Indeed, a recent market research report​ noted the global contract development and manufacturing organization (CDMO) market was valued at US$177bn in 2020, with it forecast to grow at a CAGR of 8.4% between 2021 and 2026 to reach a value of US$302bn by 2026.

Manufacturing footprint

To date, Bora has been focused on small molecule development and manufacturing.

In December last year, the CDMO finalized the acquisition of GSK's facility in Mississauga, Ontario, Canada. Initially announced in March 2020, the deal represented Bora’s first manufacturing facility in North America.

It has two facilities in Taiwan. Its Zhunan facility produces solid-dosage forms, with bottle packaging and serialization capabilities, covering 316,000-square-feet; its Tainan facility also produces solid-dosage forms, with packaging lines, covering 258,000-square-feet.

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers